Efficacy and Safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

Anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. BRAFV600-mutated (BRAFmut) melanoma patients who recur with isolated disease following adjuvant therapy may be suitable for ‘second adjuvant' treatment after local therapy. We sought to examine the efficacy and safety of ‘second adjuvant’ BRAF/MEKi.

Source: European Journal of Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Amelia M Taylor, Janet McKeown, Florentia Dimitriou, Sarah K Jacques, Lisa Zimmer, Clara Allayous, Hui-Ling Yeoh, Andrew Haydon, Julia M Ressler, Claire Galea, Rachel Woodford, Katharina Kahler, Axel Hauschild, Lucia Festino, Christoph Hoeller, Julia K Sc Tags: Original Research Source Type: research